Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Georgia Enlicitide Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter GeorgiaPolicy CP.PHAR.807

    Clinical Policy: Enlicitide (Lipfendra)

    Customize your policy alerts

    Sign up for Ambetter Georgia Policy CP.PHAR.807 alerts

    Get alerted when Policy CP.PHAR.807 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for enlicitide (Lipfendra) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C reduction and cardiovascular event risk reduction.

    Policy Summary
    PayerAmbetter Georgia
    PolicyEnlicitide (Lipfendra) coverage
    Policy CodePolicy CP.PHAR.807
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting every applicable approval criterion, including diagnosis, LDL-C results, medication history, and treatment response for continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AdultsMinimum age for initial approval
    20 mg/dayMaximum Lipfendra dose
    8 weeksPreferred PCSK9 inhibitor trial
    4 monthsEzetimibe adherence period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Approval duration
    VariesRecent LDL-C requirement

    Coverage Criteria

    Initial therapy: primary hypercholesterolemia and cardiovascular event risk reduction

    Covered when all criteria are met.

    Initial approval

    • Qualifying diagnosis or cardiovascular risk

      • Heterozygous familial hypercholesterolemia (HeFH): HeFH is diagnosed, baseline LDL-C was at least 160 mg/dL before lipid-lowering pharmacologic therapy, and the diagnosis is confirmed by a WHO/Dutch Lipid Network familial hypercholesterolemia score greater than 8 or a definite Simon Broome diagnosis.Baseline LDL-C >= 160 mg/dL; Dutch score > 8 or definite Simon Broome diagnosis
      • Primary hypercholesterolemia without HeFH: Primary hypercholesterolemia is not HeFH, baseline LDL-C was at least 190 mg/dL before lipid-lowering pharmacologic therapy, and either a genetically mediated form is confirmed by genetic testing or secondary hypercholesterolemia has been ruled out.Baseline LDL-C >= 190 mg/dL

        Secondary causes to exclude include poor diet, hypothyroidism, obstructive liver disease, renal liver disease, nephrosis, and contributory medications.

      • Increased cardiovascular event risk: Member has diabetes, a 10-year ASCVD risk of at least 10%, a CAC score of 100 to 299 Agatston units, or a qualifying ASCVD history.ASCVD risk >= 10%; CAC 100-299 Agatston units

        Qualifying ASCVD history includes acute coronary syndromes, clinically significant coronary heart disease, CAC >= 300 Agatston units, coronary or other arterial revascularization, myocardial infarction, peripheral arterial disease presumed to be atherosclerotic, stable or unstable angina, or stroke/TIA.

    • Prescriber and age: Medication is prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist, and the member is at least 18 years old.Age >= 18 years
    • Preferred PCSK9 inhibitor trial: Member failed an 8-week trial of a preferred PCSK9 inhibitor at up to maximally indicated doses, or the preferred agent is contraindicated or caused clinically significant adverse effects.8 weeks
    • Statin status: If receiving statin therapy, Lipfendra is used with a maximally tolerated statin and the member has adhered for at least 8 weeks to a high-intensity statin or to a moderate/low-intensity statin with the required prior high-intensity statin failure or skeletal-muscle symptoms on both atorvastatin and rosuvastatin. If not receiving statin therapy, statin therapy is contraindicated or the member is statin intolerant after trying at least two statins, including one hydrophilic statin, and meets the required risk-factor or SAMS rechallenge requirements.At least 8 weeks of statin adherence; at least 2 statin trials for intolerance

      Hydrophilic statins listed are pravastatin, fluvastatin, and rosuvastatin. SAMS documentation must show persistence for at least 2 weeks, resolution after discontinuation, recurrence on rechallenge, and rechallenge using the lowest dose and/or intermittent dosing.

    • Ezetimibe therapy: Member has adhered for at least 4 months to ezetimibe used concomitantly with a maximally tolerated statin, unless ezetimibe is contraindicated or previously not tolerated.4 months

      Examples of intolerance include diarrhea or upper respiratory tract infection.

    • Recent LDL-C within the last 60 days meets the threshold associated with the member's ASCVD and hypercholesterolemia risk category.>=55 mg/dL with ASCVD; >=70 mg/dL for HeFH or specified increased-risk groups; >=100 mg/dL for severe primary hypercholesterolemia without ASCVD risk factors
    • Drug regimen and dose: Treatment does not include Lerochol, Leqvio, Juxtapid, Repatha, or Praluent, and the dose does not exceed 20 mg per day.Maximum 20 mg/day

    Continuation therapy: primary hypercholesterolemia and cardiovascular event risk reduction

    Covered when all criteria are met.

    Continuation approval

    • Existing therapy or continuity of care: Member is currently receiving Lipfendra through the Centene benefit, previously met initial approval criteria, or is receiving the medication under applicable state and product continuity-of-care regulations.

      Refer to applicable state-specific continuity-of-care addenda.

    • Statin adherence when statin tolerant: If statin tolerant, documentation shows adherence to a statin at the maximally tolerated dose.
    • Positive response: Laboratory results obtained within the last 3 months show an LDL-C reduction since initiation of Lipfendra therapy.LDL-C reduction from baseline or initiation

    Non-FDA-approved indications not addressed in this policy are excluded from coverage unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label use policy or evidence of coverage documents.

    Coadministration of Lipfendra with Lerochol, Leqvio, Juxtapid, Repatha, or Praluent is not authorized. Requests that include any of these agents in the treatment plan do not meet coverage criteria.

    Clinical Thresholds and Coding Details

    Baseline LDL-C for HeFH
    PopulationMembers with heterozygous familial hypercholesterolemia (HeFH)
    Baseline LDL-CAt least 160 mg/dL before any lipid-lowering pharmacologic therapy
    Diagnosis confirmationWHO/Dutch Lipid Network score greater than 8 or a definite Simon Broome diagnosis
    Baseline LDL-C without HeFH
    PopulationPrimary hypercholesterolemia that is not HeFH
    Baseline LDL-CAt least 190 mg/dL before any lipid-lowering pharmacologic therapy
    Additional documentation

    Provider Requirements and Authorization Risks

    Prior Authorization

    Initial Approval Requires All Clinical Criteria

    Initial approval requires documentation that all applicable clinical criteria are met. The request must support the qualifying diagnosis, specialist involvement, age, required treatment history, laboratory thresholds, and safety/administrative requirements.

    • Qualifying diagnosis: HeFH with baseline LDL-C ≥ 160 mg/dL before lipid-lowering therapy and either a WHO/Dutch Lipid Network score > 8 or definite Simon Broome diagnosis; primary hypercholesterolemia that is not HeFH with baseline LDL-C ≥ 190 mg/dL plus either confirmatory genetic testing or documentation that secondary causes have been ruled out; or increased cardiovascular-event risk based on diabetes, 10-year ASCVD risk ≥ 10%, CAC score 100–299 AU, or qualifying ASCVD history.
    • For non-HeFH primary hypercholesterolemia, rule out poor diet, hypothyroidism, obstructive liver disease, renal liver disease, nephrosis, and clinically contributory medications, including glucocorticoids, sex hormones, antipsychotics, antiretrovirals, immunosuppressive agents, and retinoic acid derivatives.
    • Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist; member must be age ≥ 18 years.
    • Member must fail an 8-week trial of a preferred PCSK9 inhibitor, when applicable, at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occur. Prior authorization may be required for PCSK9 inhibitors.
    • For members receiving statin therapy, Lipfendra must be used with a statin at the maximally tolerated dose, with adherence for at least 8 weeks to a high-intensity statin or to a moderate/low-intensity statin meeting the specified prior high-intensity statin or dual-agent muscle-symptom criteria.

    Product Background

    Enlicitide (Lipfendra) is an oral proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is used as an adjunct to diet and exercise to reduce LDL-C and lower the risk of major adverse cardiovascular events in adults at increased risk when used with statins or as add-on therapy.

    Definitions

    PCSK9 inhibitor
    Full termProprotein convertase subtilisin kexin type 9 inhibitor
    AbbreviationPCSK9 inhibitor
    PurposeUsed to lower LDL-C
    HeFH
    AbbreviationHeFH
    Full termHeterozygous familial hypercholesterolemia
    Policy useA qualifying diagnosis for Lipfendra coverage when required LDL-C and diagnostic criteria are met

    Initial Therapy Criteria

    Lipfendra initial approval

    Initial therapy is covered when all policy criteria are met.

    Initial Lipfendra therapy: Adult member has a qualifying diagnosis or cardiovascular risk profile; specialist prescribing or consultation; required preferred PCSK9 inhibitor, statin, and ezetimibe history or qualifying contraindication/intolerance; recent LDL-C above the applicable threshold; no prohibited coadministration; and dose no greater than 20 mg per day.Age >= 18 years; maximum 20 mg/day

    Qualifying diagnosis or risk, treatment history, laboratory, and intolerance requirements must be documented.

    Continuation Criteria

    Lipfendra continuation approval

    Continued therapy is covered when all criteria are met.

    Continuation therapy: Member is currently receiving Lipfendra through the benefit, previously met initial criteria, or qualifies under continuity-of-care regulations; statin-tolerant members are adherent to a maximally tolerated statin; recent laboratory results show LDL-C reduction since Lipfendra initiation; prohibited coadministration is absent; and any dose increase remains at or below 20 mg per day.LDL-C reduction documented within 3 months; maximum 20 mg/day

    Step Therapy Requirements

    StepRequirementDurationExceptions or qualifying pathway
    1Trial of a preferred PCSK9 inhibitor before Lipfendra, at up to maximally indicated doses8 weeksNot required if the preferred agent is contraindicated or causes clinically significant adverse effects
    StepRequirementDurationExceptions or qualifying pathway
    2Use Lipfendra with a maximally tolerated statin and demonstrate adherence to a qualifying statin regimenAt least 8 weeksIf not receiving statin therapy, document contraindication or intolerance after trying at least two statins, including one hydrophilic statin; required statin-associated muscle symptom rechallenge documentation applies
    StepRequirementDurationExceptions or qualifying pathway
    3Use ezetimibe concomitantly with a statin at the maximally tolerated doseAt least 4 monthsNot required if ezetimibe is contraindicated or the member has a history of ezetimibe intolerance, such as diarrhea or upper respiratory tract infection

    Quantity and Dose Limits

    Lipfendra quantity limit
    MedicationLipfendra
    Maximum quantity or dose20 mg
    PeriodPer day
    Enlicitide (Lipfendra) quantity limit
    MedicationEnlicitide (Lipfendra)
    Maximum quantity or dose20 mg/day
    Dosing regimen20 mg orally once daily
    Policy Summary
    PayerAmbetter Georgia
    PolicyEnlicitide (Lipfendra) coverage
    Policy CodePolicy CP.PHAR.807
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting every applicable approval criterion, including diagnosis, LDL-C results, medication history, and treatment response for continuation requests.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsProvider Requirements and Authorization RisksProduct BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity and Dose Limits
    Drug regimen and dose: Treatment does not include Lerochol, Leqvio, Juxtapid, Repatha, or Praluent. If the request is for a dose increase, the new dose does not exceed 20 mg per day.Maximum 20 mg/day
    Genetically mediated disease confirmed by testing or secondary hypercholesterolemia ruled out
    ASCVD 10-year risk
    Risk measure10-year estimated atherosclerotic cardiovascular disease (ASCVD) risk
    Required thresholdAt least 10%
    Qualifying pathwayIncreased risk for cardiovascular events
    Coronary artery calcium thresholds
    Increased cardiovascular riskCAC score of 100 to 299 Agatston units (AU)
    ASCVD history thresholdCAC score of at least 300 AU
    MeasurementCoronary artery calcium is measured in Agatston units
    Recent LDL-C with ASCVD history
    PopulationMembers with a history of ASCVD
    Recent LDL-C thresholdAt least 55 mg/dL
    TimingLaboratory result obtained within the last 60 days
    Recent LDL-C for increased-risk groups
    Applicable populationsHeFH; severe primary hypercholesterolemia with ASCVD risk factors; or increased cardiovascular risk without ASCVD history
    Recent LDL-C thresholdAt least 70 mg/dL
    TimingLaboratory result obtained within the last 60 days
    Recent LDL-C without ASCVD risk factors
    PopulationSevere primary hypercholesterolemia without ASCVD risk factors
    Recent LDL-C thresholdAt least 100 mg/dL
    TimingLaboratory result obtained within the last 60 days
    Maximum Lipfendra dose
    MedicationLipfendra (enlicitide)
    Maximum dose20 mg per day
    Administration20 mg by mouth once daily
    HeFH cholesterol scoring
    LDL-C ≥330 mg/dL (≥8.5 mmol/L)8 points
    LDL-C 250–329 mg/dL (6.5–8.4 mmol/L)5 points
    LDL-C 190–249 mg/dL (5.0–6.4 mmol/L)3 points
    LDL-C 155–189 mg/dL (4.0–4.9 mmol/L)1 point
    Scoring methodSelect the highest score from each of five categories and add them for the total score
    Simon Broome adult threshold
    Adult total cholesterolAbove 290 mg/dL (7.5 mmol/L)
    Adult LDL-CAbove 190 mg/dL (4.9 mmol/L)
    Definition requirementOne qualifying cholesterol or LDL-level finding plus tendinous xanthomas or DNA-based evidence
    Simon Broome pediatric threshold
    Children under 16: total cholesterolAbove 260 mg/dL (6.7 mmol/L)
    Children: LDL-CAt least 4.0 mmol/L (approximately 155 mg/dL)
    Definition requirementOne qualifying cholesterol or LDL-level finding plus tendinous xanthomas or DNA-based evidence
    ASCVD risk lipid thresholds
    Lipoprotein(a)At least 125 nmol/L or at least 50 mg/dL
    TriglyceridesPersistently at least 175 mg/dL (2 mmol/L) nonfasting or at least 150 mg/dL (1.7 mmol/L) fasting
    LDL-CPersistently 160–189 mg/dL (4.1–4.9 mmol/L)
    Other lipid thresholdsNon-HDL-C 190–219 mg/dL or apoB at least 120 mg/dL
  1. Members not receiving statin therapy must have a contraindication or meet the statin-intolerance requirements, including trials of at least two statins (one hydrophilic), documented risk factors or qualifying SAMS, resolution on discontinuation, recurrence on rechallenge, and rechallenge using the lowest possible or intermittent dosing.
  2. Member must have used ezetimibe concomitantly with a maximally tolerated statin for at least 4 months, unless ezetimibe is contraindicated or intolerance is documented.
  3. Recent LDL-C, obtained within 60 days, must be ≥ 55 mg/dL with ASCVD history, ≥ 70 mg/dL with HeFH/severe primary hypercholesterolemia with ASCVD risk factors/increased cardiovascular-event risk without ASCVD history, or ≥ 100 mg/dL with severe primary hypercholesterolemia without ASCVD risk factors.
  4. The treatment plan must not include Lerochol, Leqvio, Juxtapid, Repatha, or Praluent, and the dose must not exceed 20 mg per day. Initial approval duration is 12 months.
  5. The Illinois HIM step-therapy exception under IL HB 5395 applies where specified.
  6. Prior Authorization

    Continuation Requires Documented Response

    Continuation authorization requires documented response and satisfaction of applicable continuation criteria. Submit evidence that the member remains eligible for therapy and is benefiting from Lipfendra.

    • Member is receiving the medication through the Centene benefit, previously met initial approval criteria, or qualifies under applicable state and product continuity-of-care regulations.
    • If statin tolerant, document adherence to a statin at the maximally tolerated dose.
    • Document a positive response with laboratory results from within the last 3 months showing an LDL-C reduction since Lipfendra was initiated.
    • For dose increases, the new dose must not exceed 20 mg per day; continuation approval duration is 12 months.
    • The treatment plan must not include coadministration with Lerochol, Leqvio, Juxtapid, Repatha, or Praluent.
    Step Therapy

    Preferred PCSK9 and Statin Step Therapy

    Preferred PCSK9 inhibitor and statin step therapy must be completed when applicable. Document treatment failure, contraindication, or clinically significant adverse effects before requesting Lipfendra.

    • Document failure of an 8-week trial of a preferred PCSK9 inhibitor at up to maximally indicated doses, unless contraindicated or not tolerated because of clinically significant adverse effects.
    • For members on statin therapy, use Lipfendra with a statin at the maximally tolerated dose and document at least 8 weeks of adherence to the applicable statin regimen.
    • For moderate- or low-intensity statin use, document either an inadequate response after at least 8 continuous weeks of a high-intensity statin or skeletal-muscle symptoms with both rosuvastatin and atorvastatin that resolved after discontinuation.
    • For members not on statin therapy, document a contraindication or statin intolerance, including trials of at least two statins with one hydrophilic agent and the required risk-factor/SAMS history.
    • Prior authorization may be required for PCSK9 inhibitors. The Illinois HIM exception under IL HB 5395 removes the specified step-therapy requirements.

    Unsupported block type: step_therapy

    Documentation Required

    Required Clinical Documentation

    Submit clinical documentation supporting every applicable approval criterion. Office chart notes, laboratory results, and other clinical information must establish the diagnosis, treatment history, response, and requested dose.

    • Include baseline LDL-C before lipid-lowering pharmacologic therapy, the applicable HeFH or primary-hypercholesterolemia diagnostic evidence, and documentation of cardiovascular risk or ASCVD history.
    • Include specialist prescribing or consultation, member age, PCSK9 inhibitor trial or exception, statin use/intolerance or contraindication, statin adherence, and the 4-month ezetimibe adherence period or applicable exception.
    • Include a recent LDL-C result obtained within 60 days for initial approval, and for continuation include laboratory results within the last 3 months showing LDL-C reduction since Lipfendra initiation.
    • Document the treatment plan, requested dose, absence of prohibited coadministration, and—when applicable—reasons for dose increase or continuation under continuity-of-care rules.
    Denial Risk

    Denial Risks: Drug Combinations and Dose

    Do not request Lipfendra with prohibited coadministration or at an excessive dose. Either condition is a denial risk for initial or continued authorization.

    • The treatment plan must not include Lerochol, Leqvio, Juxtapid, Repatha, or Praluent.
    • The Lipfendra dose must not exceed 20 mg per day, including when requesting a dose increase.

    Unsupported block type: denial_risk

    Note

    Other Indications: Refer for Applicable Review

    Other indications require review under the applicable coverage pathway. Do not submit these requests as routine Lipfendra approvals under the primary hypercholesterolemia criteria.

    • If a label change within the last 6 months is not reflected in the policy, refer formulary drugs to the applicable no-coverage criteria policy: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
    • For drugs not on the formulary or PDL, refer to the applicable non-formulary policy: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • If the requested diagnosis, age, or dosing regimen is not specifically listed under the non-covered indications section and the recent-label-change criterion does not apply, refer to the applicable off-label policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
    ASCVD
    AbbreviationASCVD
    Full termAtherosclerotic cardiovascular disease
    Policy relevanceASCVD history requires a recent LDL-C of at least 55 mg/dL for the applicable coverage pathway
    CAC
    AbbreviationCAC
    Full termCoronary artery calcium
    Measurement unitAgatston units (AU)
    SAMS
    AbbreviationSAMS
    Full termStatin-associated muscle symptoms
    Typical symptomsMuscle pain, aching, cramps, or weakness
    Definite HeFH by point score
    Total scoreGreater than 8 indicates definite familial hypercholesterolemia
    Scoring methodChoose the highest score from each category and add the scores
    Five categoriesFamily history, clinical history, physical examination, cholesterol levels, and DNA analysis
    Simon Broome definite familial hypercholesterolemia
    Cholesterol or LDL-C criterionTotal cholesterol above 290 mg/dL in adults, above 260 mg/dL in children under 16, or LDL-C above 190 mg/dL in adults (4.0 mmol/L in children)
    Physical findingTendinous xanthomas in the patient or a qualifying relative
    Genetic findingDNA-based evidence of an LDL receptor mutation or familial defective apo B100
    Typical statin-associated muscle symptoms
    Typical symptomsBilateral muscle pain, aching, cramps, or weakness
    Common muscle groupsLarge muscle groups, including the thigh, buttock, back, and shoulder girdle
    Strongest supporting evidenceSymptoms recur with statin rechallenge and disappear after statin discontinuation